These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27748860)

  • 1. Bone morphogenetic protein‑9 promotes the differentiation of mouse spleen macrophages into osteoclasts via the ALK1 receptor and ERK 1/2 pathways in vitro.
    Li H; Zhao D; Wang S; Ding J; Zhao L
    Mol Med Rep; 2016 Nov; 14(5):4545-4550. PubMed ID: 27748860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone morphogenetic protein-9 activates Smad and ERK pathways and supports human osteoclast function and survival in vitro.
    Fong D; Bisson M; Laberge G; McManus S; Grenier G; Faucheux N; Roux S
    Cell Signal; 2013 Apr; 25(4):717-28. PubMed ID: 23313128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum/glucocorticoid-regulated kinase 1 as a novel transcriptional target of bone morphogenetic protein-ALK1 receptor signaling in vascular endothelial cells.
    Araki M; Hisamitsu T; Kinugasa-Katayama Y; Tanaka T; Harada Y; Nakao S; Hanada S; Ishii S; Fujita M; Kawamura T; Saito Y; Nishiyama K; Watanabe Y; Nakagawa O
    Angiogenesis; 2018 May; 21(2):415-423. PubMed ID: 29478089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BMP9 Induces Cord Blood-Derived Endothelial Progenitor Cell Differentiation and Ischemic Neovascularization via ALK1.
    Kim J; Kim M; Jeong Y; Lee WB; Park H; Kwon JY; Kim YM; Hwang D; Kwon YG
    Arterioscler Thromb Vasc Biol; 2015 Sep; 35(9):2020-31. PubMed ID: 26229139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TGFbeta/BMP type I receptors ALK1 and ALK2 are essential for BMP9-induced osteogenic signaling in mesenchymal stem cells.
    Luo J; Tang M; Huang J; He BC; Gao JL; Chen L; Zuo GW; Zhang W; Luo Q; Shi Q; Zhang BQ; Bi Y; Luo X; Jiang W; Su Y; Shen J; Kim SH; Huang E; Gao Y; Zhou JZ; Yang K; Luu HH; Pan X; Haydon RC; Deng ZL; He TC
    J Biol Chem; 2010 Sep; 285(38):29588-98. PubMed ID: 20628059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
    Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
    Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling.
    Yamashita M; Otsuka F; Mukai T; Yamanaka R; Otani H; Matsumoto Y; Nakamura E; Takano M; Sada KE; Makino H
    Regul Pept; 2010 Jun; 162(1-3):99-108. PubMed ID: 20346376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of bone morphogenetic protein 9 (BMP9) as a novel profibrotic factor in vitro.
    Muñoz-Félix JM; Cuesta C; Perretta-Tejedor N; Subileau M; López-Hernández FJ; López-Novoa JM; Martínez-Salgado C
    Cell Signal; 2016 Sep; 28(9):1252-1261. PubMed ID: 27208502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor 2 inhibits bone morphogenetic protein 9-induced osteogenic differentiation of mesenchymal stem cells by repressing Smads signaling and subsequently reducing Smads dependent up-regulation of ALK1 and ALK2.
    Song T; Wang W; Xu J; Zhao D; Dong Q; Li L; Yang X; Duan X; Liang Y; Xiao Y; Wang J; He J; Tang M; Wang J; Luo J
    Int J Biochem Cell Biol; 2013 Aug; 45(8):1639-46. PubMed ID: 23680673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WSS25, a sulfated polysaccharide, inhibits RANKL-induced mouse osteoclast formation by blocking SMAD/ID1 signaling.
    Chen C; Qin Y; Fang JP; Ni XY; Yao J; Wang HY; Ding K
    Acta Pharmacol Sin; 2015 Sep; 36(9):1053-64. PubMed ID: 26299951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BMP9 Reduces Bone Loss in Ovariectomized Mice by Dual Regulation of Bone Remodeling.
    Zhou YM; Yang YY; Jing YX; Yuan TJ; Sun LH; Tao B; Liu JM; Zhao HY
    J Bone Miner Res; 2020 May; 35(5):978-993. PubMed ID: 31914211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone morphogenetic protein 2 enhances mouse osteoclast differentiation via increased levels of receptor activator of NF-κB ligand expression in osteoblasts.
    Tachi K; Takami M; Zhao B; Mochizuki A; Yamada A; Miyamoto Y; Inoue T; Baba K; Kamijo R
    Cell Tissue Res; 2010 Nov; 342(2):213-20. PubMed ID: 20941510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium/calmodulin-dependent kinase activity is required for efficient induction of osteoclast differentiation and bone resorption by receptor activator of nuclear factor kappa B ligand (RANKL).
    Ang ES; Zhang P; Steer JH; Tan JW; Yip K; Zheng MH; Joyce DA; Xu J
    J Cell Physiol; 2007 Sep; 212(3):787-95. PubMed ID: 17477372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation.
    Sundaram K; Nishimura R; Senn J; Youssef RF; London SD; Reddy SV
    Exp Cell Res; 2007 Jan; 313(1):168-78. PubMed ID: 17084841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulsed electromagnetic fields inhibit osteoclast differentiation in RAW264.7 macrophages via suppression of the protein kinase B/mammalian target of rapamycin signaling pathway.
    Lei Y; Su J; Xu H; Yu Q; Zhao M; Tian J
    Mol Med Rep; 2018 Jul; 18(1):447-454. PubMed ID: 29749519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BMP9 induces EphrinB2 expression in endothelial cells through an Alk1-BMPRII/ActRII-ID1/ID3-dependent pathway: implications for hereditary hemorrhagic telangiectasia type II.
    Kim JH; Peacock MR; George SC; Hughes CC
    Angiogenesis; 2012 Sep; 15(3):497-509. PubMed ID: 22622516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.